Multiplexed Targeting of Barrett's Neoplasia with a Heterobivalent Ligand: Imaging Study on Mouse Xenograft in Vivo and Human Specimens Ex Vivo

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2018 Jun 6

PMID 29870260

Citations 9

Authors

Jing Chen

Juan Zhou

Zhenghong Gao

Xue Li

Fa Wang

Xiyu Duan

Gaoming Li

Bishnu P Joshi

Rork Kuick

Henry D Appelman

Thomas D Wang

Affiliations

Soon will be listed here.

Abstract

Esophageal adenocarcinoma (EAC) is a molecularly heterogeneous disease that is rising rapidly in incidence and has poor prognosis. We developed a heterobivalent peptide to target detection of early Barrett's neoplasia by combining monomer heptapeptides specific for either EGFR or ErbB2 in a heterodimer configuration. The structure of a triethylene glycol linker was optimized to maximize binding interactions to the surface receptors on cells. The Cy5.5-labeled heterodimer QRH*-KSP*-E3-Cy5.5 demonstrated specific binding to each target and showed 3-fold greater fluorescence intensity and 2-fold higher affinity compared with those of either monomer alone. Peak uptake in xenograft tumors was observed at 2 h postinjection with systemic clearance by ∼24 h in vivo. Furthermore, ligand binding was evaluated on human esophageal specimens ex vivo, and 88% sensitivity and 87% specificity were found for the detection of either high-grade dysplasia (HGD) or EAC. This peptide heterodimer shows promise for targeted detection of early Barrett's neoplasia in clinical study.

Citing Articles

Flexible fiber cholangioscope for detection of near-infrared fluorescence.

Chang T, Zhou Y, Zhang R, Kwon R, Wamsteker E, Turgeon D VideoGIE. 2023; 8(3):110-112.

PMID: 36935809 PMC: 10019950. DOI: 10.1016/j.vgie.2022.10.013.

Detection of Barrett's neoplasia with a near-infrared fluorescent heterodimeric peptide.

Chen J, Jiang Y, Chang T, Rubenstein J, Kwon R, Wamsteker E Endoscopy. 2022; 54(12):1198-1204.

PMID: 35299273 PMC: 9718637. DOI: 10.1055/a-1801-2406.

Cranberry Polyphenols in Esophageal Cancer Inhibition: New Insights.

Weh K, Zhang Y, Howard C, Howell A, Clarke J, Kresty L Nutrients. 2022; 14(5).

PMID: 35267943 PMC: 8912450. DOI: 10.3390/nu14050969.

Thin Layer-Protected Gold Nanoparticles for Targeted Multimodal Imaging with Photoacoustic and CT.

Chen J, Nguyen V, Jaiswal S, Kang X, Lee M, Paulus Y Pharmaceuticals (Basel). 2021; 14(11).

PMID: 34832857 PMC: 8624483. DOI: 10.3390/ph14111075.

A Remote Secondary Binding Pocket Promotes Heteromultivalent Targeting of DC-SIGN.

Wawrzinek R, Wamhoff E, Lefebre J, Rentzsch M, Bachem G, Domeniconi G J Am Chem Soc. 2021; 143(45):18977-18988.

PMID: 34748320 PMC: 8603350. DOI: 10.1021/jacs.1c07235.

References

Becker A, Hessenius C, Licha K, Ebert B, Sukowski U, Semmler W . Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol. 2001; 19(4):327-31. DOI: 10.1038/86707. View

Tangri S, LiCalsi C, Sidney J, Sette A . Rationally engineered proteins or antibodies with absent or reduced immunogenicity. Curr Med Chem. 2002; 9(24):2191-9. DOI: 10.2174/0929867023368647. View

Bray B . Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov. 2003; 2(7):587-93. DOI: 10.1038/nrd1133. View

Miller C, Moy J, Lin L, Schipper M, Normolle D, Brenner D . Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin Cancer Res. 2003; 9(13):4819-25. View

Dahlberg P, Jacobson B, Dahal G, Fink J, Kratzke R, Maddaus M . ERBB2 amplifications in esophageal adenocarcinoma. Ann Thorac Surg. 2004; 78(5):1790-800. DOI: 10.1016/j.athoracsur.2004.05.037. View

Handl H, Vagner J, Han H, Mash E, Hruby V, Gillies R . Hitting multiple targets with multimeric ligands. Expert Opin Ther Targets. 2004; 8(6):565-86. DOI: 10.1517/14728222.8.6.565. View

Landers K, Burger M, Tebay M, Purdie D, Scells B, Samaratunga H . Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer. 2004; 114(6):950-6. DOI: 10.1002/ijc.20760. View

Wu A, Senter P . Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005; 23(9):1137-46. DOI: 10.1038/nbt1141. View

Citri A, Yarden Y . EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006; 7(7):505-16. DOI: 10.1038/nrm1962. View

10.

Vagner J, Xu L, Handl H, Josan J, Morse D, Mash E . Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors. Angew Chem Int Ed Engl. 2008; 47(9):1685-8. PMC: 2716288. DOI: 10.1002/anie.200702770. View

11.

Li Z, Wu Z, Chen K, Ryu E, Chen X . 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med. 2008; 49(3):453-61. DOI: 10.2967/jnumed.107.048009. View

12.

Liu Z, Yan Y, Chin F, Wang F, Chen X . Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem. 2008; 52(2):425-32. DOI: 10.1021/jm801285t. View

13.

Xu L, Vagner J, Josan J, Lynch R, Morse D, Baggett B . Enhanced targeting with heterobivalent ligands. Mol Cancer Ther. 2009; 8(8):2356-65. PMC: 3662534. DOI: 10.1158/1535-7163.MCT-08-1183. View

14.

Lee S, Xie J, Chen X . Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev. 2010; 110(5):3087-111. PMC: 2868934. DOI: 10.1021/cr900361p. View

15.

Yan Y, Chen X . Peptide heterodimers for molecular imaging. Amino Acids. 2010; 41(5):1081-92. PMC: 3619030. DOI: 10.1007/s00726-010-0546-y. View

16.

Cochran J . Engineered proteins pull double duty. Sci Transl Med. 2010; 2(17):17ps5. DOI: 10.1126/scitranslmed.3000276. View

17.

Thakur A, Lum L . Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther. 2010; 12(3):340-9. PMC: 3785321. View

18.

Yan Y, Chen K, Yang M, Sun X, Liu S, Chen X . A new 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging. Amino Acids. 2010; 41(2):439-47. PMC: 3102790. DOI: 10.1007/s00726-010-0762-5. View

19.

Cronin J, McAdam E, Danikas A, Tselepis C, Griffiths P, Baxter J . Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE). Am J Gastroenterol. 2010; 106(1):46-56. DOI: 10.1038/ajg.2010.433. View

20.

Abrams J . Chemoprevention of esophageal adenocarcinoma. Therap Adv Gastroenterol. 2010; 1(1):7-18. PMC: 3002491. DOI: 10.1177/1756283X08093568. View